Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
| Status: | Archived |
|---|---|
| Conditions: | Blood Cancer, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2010 |
| End Date: | March 2012 |
A Phase 1 Study of XmAb®5574 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
This is an open-label, multi-dose, single-arm, Phase 1, dose-escalation study of XmAb5574.
The study will be conducted to identify the maximum tolerated dose (MTD) and/or recommended
dose(s) (RD) for further study, to characterize safety and tolerability, to characterize PK,
PD and immunogenicity, and to evaluate preliminary antitumor activity of XmAb5574 in
patients with relapsed or refractory CLL/SLL.
We found this trial at
2
sites
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Click here to add this to my saved trials
Sarah Cannon Cancer Center People who live with cancer
Click here to add this to my saved trials